BTSS Boehringer Ingelheim Award for Excellence in Biotherapeutic Safety
BTSS Boehringer Ingelheim Award for Excellence in Biotherapeutic Safety supports graduate students and postdocs attending conferences and training to build careers in nonclinical biotherapeutic safety.
Funder: Society of Toxicology
Due Dates: August 14, 2026 (Applications open) | January 8, 2027 (Application deadline)
Funding Amounts: Up to $2,000 in reimbursement for conference or training expenses
Summary: Supports graduate students and postdoctoral researchers attending conferences or training for careers in nonclinical biotherapeutic safety.
Key Information: Applicants must attend the SOT Annual Meeting during the year of application.
Description
The Society of Toxicology’s BTSS Boehringer Ingelheim Award for Excellence in Biotherapeutic Safety encourages research and training among graduate students and postdoctoral researchers in nonclinical safety sciences applied to biotherapeutic products. It supports attendance at relevant conferences, professional workshops, and training courses, emphasizing their value to the applicant’s future career.
The scientific scope includes biotechnology-derived proteins, gene therapies, vaccines, blood-derived products, imaging agents, and molecular diagnostics. It also encompasses genetically modified crops, foods, and animals, biodegradable plastics, biofuels, biodefense, and bioremediation. The award is supported by the Boehringer Ingelheim Biotherapeutic Safety Excellence Endowment Fund, with recipients selected by the BTSS awards committee.
